11beta-hydroxysteroid dehydrogenase

This is an abbreviated version, for detailed information about 11beta-hydroxysteroid dehydrogenase, go to the full flat file.


an 11beta-hydroxysteroid
an 11-oxosteroid


11 beta-hydroxysteroid dehydrogenase type 1, 11-beta-HSD1, 11-beta-HSD1 (oxidase) NADP+, 11-beta-HSD2, 11-beta-hydroxysteroid dehydrogenase type1, 11-DH, 11-DH2, 11-oxoreductase, 11beta hydroxysteroid dehydrogenase type 1, 11beta-HSD, 11beta-HSD 1, 11beta-HSD type 1, 11beta-HSD-1, 11beta-HSD-2, 11beta-HSD1, 11beta-HSD1A, 11beta-HSD2, 11beta-hydroxy steroid dehydrogenase, 11beta-hydroxysteroid dehydrogenase, 11beta-hydroxysteroid dehydrogenase 1, 11beta-hydroxysteroid dehydrogenase isoforms 1, 11beta-hydroxysteroid dehydrogenase type 1, 11beta-hydroxysteroid dehydrogenase type 2, 11beta-hydroxysteroid dehydrogenase type I, 11beta-hydroxysteroid dehydrogenase type-1, 11beta-hydroxysteroid dehydrogenase-1, 11beta-hydroxysteroid dehydrogenases type 1, 11beta-hydroxysteroid-dehydrogenase type I, 11betaHSD1, 11betaHSD2, 11HSD1, beta-hydroxysteroid dehydrogenase, corticosteroid 11-reductase, corticosteroid 11beta-dehydrogenase, dehydrogenase, 11beta-hydroxy steroid, HSD1, HSD11B, HSD11B1, Hsd11B2, hydroxysteroid (11-beta) dehydrogenase, isozyme 11beta-HSD1, More, NAD-dependent 11-beta-hydroxysteroid dehydrogenase, NADP(+)-dependent 11beta-dehydrogenase, NADP+-dependent 11beta-hydroxysteroid dehydrogenase 1, type 1 11beta-hydroxysteroid dehydrogenase


     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
       11beta-hydroxysteroid dehydrogenase


Crystallization on EC - 11beta-hydroxysteroid dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
purified recombinant isozyme 11beta-HSD1 in complex with substrate, cofactor and analogue, or inhibitor, 10 mg/ml protein in 20 mM Tris-HCl, pH 8.0, 2mM Tris(carboxyethyl)phosphine, 5% glycerol, 0.5 M guanidinum hydrochloride, 0.05% Anapoe X-100, 0.02 mM cortisone, and 0.04 mM NADP+ analogue 3-aminopyridine adenine dinucleotide phosphate AADP, NADP+, BVT-4584, or cortisone, hanging drop vapour diffusion method, mixing with equal volume of precipitation solution containing 38-40% PEG 550 mono methyl ether, and 0.1 M Bis-Tris, pH 6.5, equlibration against 1 ml precipitation solution, 5-6 days, X-ray diffraction structure determination and analysis at 2.5 A resolution
11beta-HSD1 (24-292) C272S mutant, hanging drop vapour diffusion method, using 25% (w/v) PEG 3350, 0.2 M ammonium acetate, and 0.1 M sodium citrate buffer (pH 5.6)
11beta-HSD1 residues 24-292 C272S, hanging drop vapour diffusion method, using 100 mM HEPES pH 6.8-7.1 and 16-18% (w/v) PEG 3350
analysis of substratebinding by threedimensional modeling. There are favorable interactions between the C7-hydroxyl group of substrate and the catalytic site when the A ring of substrate is oriented towards the interior of the enzyme
co-crystal structure of inhibitor 8-[[(2-cyanopyridin-3-yl)methyl]sulfanyl]-6-hydroxy-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile with enzyme and cofactor NADP+. Structure shows a critical H-bonding interaction between the OH pharmacophore of the inhibitor and the side chains of S170 and Y183 residues at the catalytic site of the enzyme
docking of cortisone into the catalytic site of wild type and mutant Y177A, PDB entry 2BEL. The catalytic site is stabilised in the enzyme dimer. Residues K44, N123, and T222 at the bottom of the cavity define a small functional back-door that allows water to enter or exit, making it easier for the substrate to leave or occupy the site. Residue Y177 is involved in stabilising interactions with the A ring of the substrate
in complex with inhibitor 2-[(3,3-dimethylpiperidin-1-yl)carbonyl]-6-(3-fluoro-4-methylphenyl)pyridine. The carbonyl oxygen of the inhibitor is within hydrogen bonding distance to active site residues S170 and Y183, the inhibitor also forms hydrophobic interactions with the protein
purified recombinant isozyme 11beta-HSD1 catalytic domain mutant C272S, the nanovolume crystallization method, the reservoir solution contains 20% PEG 3350, and 0.1 M MES, pH 6.2, soaking of crystals in 1 mM lutetium acetate reservoir solution, two crystal forms, X-ray diffraction structure determination and analysis at 1.55-2.45 A resolution
sitting drop vapour diffusion method, using 16-18% (w/v) PEG3350 and 0.1 M MES buffer (pH 6.2-6.4)
purified recombinant His6-tagged enzyme, hanging drop vapour diffusion method, 25 mg/ml protein in 20 mM Tris-HCl, pH 8.0, 0.2 M NaCl, 0.1% Triton, 5% glycerol, and 2 mM EDTA, mixed with equal volume of well solution containing 1.8 M Li2O4, and 0.1 M HEOES, pH 7.5, at room temperature, derivatization with 1 mM ethylmercuric chloride, soaking of crystals with NADH and corticoserone containing solution, X-ray diffraction structure determination and analysis at 3.0 A resolution